Antiperspirant Duration Claims Limit Revision Sought By CTFA
This article was originally published in The Tan Sheet
Executive Summary
FDA should revoke the provision in the OTC Antiperspirant Drug Products Final Monograph limiting duration of efficacy claims to 24 hours, the Cosmetic, Toiletry & Fragrance Association contends in a July 8 petition to the agency
You may also be interested in...
Antiperspirant Duration Claim Restrictions Contested By CTFA
Restricting enhanced duration claims under the OTC Antiperspirant Drug Products Final Monograph violates First Amendment principles and is inconsistent with FDA regulatory precedent, according to the Cosmetic, Toiletry & Fragrance Association
Antiperspirant Duration Claim Restrictions Contested By CTFA
Restricting enhanced duration claims under the OTC Antiperspirant Drug Products Final Monograph violates First Amendment principles and is inconsistent with FDA regulatory precedent, according to the Cosmetic, Toiletry & Fragrance Association
Antiperspirant Duration Claim Restrictions Contested By CTFA
Restricting enhanced duration claims under the OTC Antiperspirant Drug Products Final Monograph violates First Amendment principles and is inconsistent with FDA regulatory precedent, according to the Cosmetic, Toiletry & Fragrance Association